Performance characteristics of the Architect® brain natriuretic peptide (BNP) assay: A two site study

Mongia, Shella K.; La’ulu, Sonia L.; Apple, Fred S.; Ler, Ranka; Murakami, MaryAnn M.; Roberts, William L.

doi:10.1016/j.cca.2008.01.026

Cited by 15 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Clinical BNP 1-32 was measured by standard clinical laboratory assay techniques using the Beckman assay on the DXI analyzer. 17 ProBNP levels were determined at Ortho-Clinical Diagnostics (Raritan, NJ) using Hytest antibodies (Hytest 18H5, NT-proBNP). 10 The specifications of this assay indicate Ͻ1.5% cross-reactivity with BNP and NT-proBNP.…”

Section: Methodsmentioning

confidence: 99%

Comparison of Mass Spectrometry and Clinical Assay Measurements of Circulating Fragments of B-Type Natriuretic Peptide in Patients With Chronic Heart Failure

Miller

Phelps

Wood

et al. 2011

Circ: Heart Failure

107

View full text Add to dashboard Cite

Background-Multiple B-type natriuretic peptide (BNP) fragments circulate in patients with heart failure (HF) but the types and relative quantities, particularly in relation to bioactive BNP 1-32, remain poorly defined. The purpose of the study was to relate clinically available BNP values with quantitative information on the concentration of pre-secretion and post-processed fragments of BNP detected by mass spectrometry. Methods and Results-Seventy Class I-IV patients were prospectively enrolled with blood drawn into tubes containing a preservative to protect against BNP degradation.

show abstract

Section: Methodsmentioning

confidence: 99%

Comparison of Mass Spectrometry and Clinical Assay Measurements of Circulating Fragments of B-Type Natriuretic Peptide in Patients With Chronic Heart Failure

Miller

Phelps

Wood

et al. 2011

Circ: Heart Failure

107

View full text Add to dashboard Cite

show abstract

“…BNP and NT-proBNP concentrations in arterial (BNP A and NT-proBNP A ) and coronary sinus (BNP CS and NT-proBNP CS ) plasma were measured using the ARCHITECT BNP assay (Abbott) 13 and Roche Elecsys proBNP assay on the E170 analyzer (Roche). 14 The within and total coefficients of variation for ARCHITECT assay and the Elecsys proBNP assay are Յ5.3% and Ͻ3.0%, respectively.…”

Section: Laboratory Analysismentioning

confidence: 99%

“…14 The within and total coefficients of variation for ARCHITECT assay and the Elecsys proBNP assay are Յ5.3% and Ͻ3.0%, respectively. 13,14 Transcardiac BNP (⌬ A-CS BNP) and NTproBNP (⌬ A-CS NT-proBNP) gradients were calculated as concentration in coronary sinus blood minus concentration in arterial blood. In the majority of patients, venous blood samples taken from the introducer sheath in the internal jugular vein or from an antecubital vein were analyzed for BNP (BNP V ; nϭ35) and NT-proBNP (NT-proBNP V ; nϭ40).…”

Section: Laboratory Analysismentioning

confidence: 99%

Hemodynamic Determinants of Myocardial B-Type Natriuretic Peptide Release

2010

View full text Add to dashboard Cite

Abstract-Although B-type natriuretic peptide (BNP) is widely used as a biomarker for heart failure, the in vivo mechanical stimulus for its cardiac release remains poorly defined. We aimed to characterize the hemodynamic determinants of the transcardiac BNP gradient as a measure of myocardial BNP release by performing a detailed hemodynamic assessment in subjects with a broad spectrum of systolic and diastolic left ventricular dysfunction. Forty-two subjects underwent a detailed transthoracic echocardiographic study, right heart catheterization, and simultaneous BNP measurement in arterial and coronary sinus plasma. The transcardiac BNP gradient was lowest in subjects with normal left ventricular ejection fraction/high peak early diastolic annular velocity (nϭ11), intermediate in those with normal left ventricular ejection fraction/low peak early diastolic annular velocity (nϭ13), and highest in those with low left ventricular ejection fraction/low peak early diastolic annular velocity (nϭ18; 29 ng/L (range: 15 to 78 ng/L) versus 88 ng/L (range: 34 to 172 ng/L) versus 1566 ng/L (range: 624 to 2349 ng/L; PϽ0.001). Across the range of patients, left ventricular end-systolic wall stress (r 2 ϭ0.51) and peak systolic mitral annular velocity (r 2 ϭ0.47) showed the strongest correlation with higher transcardiac BNP gradient. In contrast, the transcardiac BNP gradient was weakly related to indices of diastolic load, including pulmonary capillary wedge pressure (r 2 ϭ0.27) and left ventricular end-diastolic wall stress (r 2 ϭ0.21). Across this spectrum of pathophysiology, left ventricular end-systolic wall stress appears to be the key mechanical stimulus influencing cardiac BNP release. (Hypertension. 2010;56:682-689.)

show abstract

“…[15][16][17][18][19] To use these tests for monitoring, it is necessary to use an automated assay system with low inter-assay and intra-assay coefficients of variations. 16,20, 21 Therefore, we first evaluated the biological variation (2-month interval) for BNP using an automated assay system in 133 outpatients with NICHF who had remained clinically stable after discharge (median 11.6 months). Thereafter, we prospectively followed these patients for a mean follow-up period of 42 months and evaluated the relationship between the cardiac events and the values of BNP (at baseline and after 2 months) and the changes of BNP in stable outpatients with NICHF.…”

mentioning

confidence: 99%

Biological Variation of Brain Natriuretic Peptide and Cardiac Events in Stable Outpatients With Nonischemic Chronic Heart Failure

Nishiyama

Tsutamoto

Yamaji

et al. 2011

Circ J

View full text Add to dashboard Cite

Background: To evaluate the biological variation and prognostic value of brain natriuretic peptide (BNP) for stable outpatients with nonischemic chronic heart failure (NICHF). Methods and Results:Biological variation in BNP was evaluated using an automated assay system in 140 outpatients with NICHF. The stable clinical condition during the 2-month study period was defined as unchanged NYHA and unchanged left ventricular ejection fraction; therefore, 7 patients were excluded during the 2 months. Thereafter, 133 patients were prospectively followed and the relationship between cardiac events and the plasma BNP concentrations (at baseline and after 2 months) were evaluated as well as the changes in BNP. The biological variation in BNP (2-month interval) was calculated as 22.3%. During a mean follow-up period of 42 months, 26 patients had cardiac events. According to stepwise multivariate analyses, plasma BNP after 2 months (P= 0.0002) and % change in BNP (P=0.0067) were significant independent predictors of cardiac events. Conclusions:These findings indicated that a combination of the absolute value of BNP after 2 months and % increase in BNP (2-month interval) is useful for predicting cardiac events in stable outpatients with NICHF. (Circ J 2011; 75: 341 - 347)

show abstract

Performance characteristics of the Architect® brain natriuretic peptide (BNP) assay: A two site study

Cited by 15 publications

References 9 publications

Comparison of Mass Spectrometry and Clinical Assay Measurements of Circulating Fragments of B-Type Natriuretic Peptide in Patients With Chronic Heart Failure

Comparison of Mass Spectrometry and Clinical Assay Measurements of Circulating Fragments of B-Type Natriuretic Peptide in Patients With Chronic Heart Failure

Hemodynamic Determinants of Myocardial B-Type Natriuretic Peptide Release

Biological Variation of Brain Natriuretic Peptide and Cardiac Events in Stable Outpatients With Nonischemic Chronic Heart Failure

Contact Info

Product

Resources

About